PDS Biotechnology (NASDAQ:PDSB) Shares Down 1.9% – Here’s What Happened

PDS Biotechnology Corporation (NASDAQ:PDSB) traded down 1.9% during trading on Tuesday . The stock traded as low as $0.8746 and last traded at $0.9010. 355,481 shares changed hands during trading, a decline of 40% from the average session volume of 595,547 shares. The stock had previously closed at $0.9186.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PDSB. HC Wainwright boosted their price target on PDS Biotechnology from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Wednesday, October 8th. Finally, B. Riley lowered their target price on shares of PDS Biotechnology from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, November 25th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, PDS Biotechnology has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Price Performance

The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $44.13 million, a P/E ratio of -1.10 and a beta of 1.11. The company has a 50 day moving average price of $0.90 and a 200 day moving average price of $1.14.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. On average, equities analysts predict that PDS Biotechnology Corporation will post -1.2 EPS for the current fiscal year.

Hedge Funds Weigh In On PDS Biotechnology

A number of large investors have recently made changes to their positions in PDSB. Armistice Capital LLC bought a new stake in PDS Biotechnology in the 1st quarter valued at $5,259,000. Iron Gate Global Advisors LLC acquired a new stake in shares of PDS Biotechnology during the first quarter worth $89,000. Tempus Wealth Planning LLC boosted its position in shares of PDS Biotechnology by 154.3% in the second quarter. Tempus Wealth Planning LLC now owns 47,800 shares of the company’s stock valued at $64,000 after acquiring an additional 29,000 shares during the period. Marshall Wace LLP acquired a new position in shares of PDS Biotechnology in the second quarter valued at about $91,000. Finally, Jane Street Group LLC acquired a new position in shares of PDS Biotechnology in the second quarter valued at about $92,000. Institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.